Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.75 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Perry A. Karsen

Chief Executive Officer of Celgene Cellular Therapeutics,Celgene Corporation
AgeTotal Calculated CompensationThis person is connected to 35 board members in 5 different organizations across 11 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Perry A. Karsen serves as the President of Stalar 4, Inc. and Stalar 3 Inc. Mr. Karsen serves as an Executive Officer of Healthcare IT, Inc. He serves as the Chief Executive Officer of Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene Corporation since May 2013. He was General Partner at Midtown Fund III and FirstMark IV, L.P. Mr. Karsen served as the Chief Operations Officer of Celgene Corporation since July 2010 until August 1, 2014, and its Executive ...

Read Full Background

Corporate Headquarters*

86 Morris Avenue
Summit, New Jersey 07901

United States

Phone: 908-673-9000
Fax: --

Board Members Memberships*

President and Director
President and Director


Master's Degree
Duke University
University of Illinois-Urbana-Champaign
Master's Degree
J.L. Kellogg School of Management, Northwestern University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$666,500

Stock Options*

Restricted Stock Awards$368,088
All Other Compensation$24,440
Exercised Options125,192
Exercised Options Value$8,114,178
Exercisable Options68,368
Unexercisable Options201,153
Total Value of Options$8,114,178
Total Number of Options394,713

Total Compensation*

Total Annual Cash Compensation$4,813,454
Total Short Term Compensation$666,500
Other Long Term Compensation$392,528
Total Calculated Compensation$7,259,162
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CELGZ:US $1.75 USD 0.00


Giovanni Caforio M.D.Chief Executive Officer and Director
Bristol-Myers Squibb Company
George A. Scangos Ph.D.Chief Executive Officer and Director
Biogen Inc.
Omar S. Ishrak Chairman and Chief Executive Officer
Medtronic plc
John C. Lechleiter Ph.D.Chairman, Chief Executive Officer and President
Eli Lilly and Company
J. Michael Pearson Chairman and Chief Executive Officer
Valeant Pharmaceuticals International, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP-CVR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at